Characterization of Gut Microbiota in Chronic Liver Disease With Decreased Muscle Mass
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 283
- Locations
- 1
- Primary Endpoint
- Fecal gut microbiota between sarcopenia group and non-sarcopenia group
Study Overview
Brief Summary
The purpose of this study was to confirm the presence of specific gut microbiota observed in patients with sarcopenia among patients who agreed to analyze gut microbiota through stool among multi-center chronic liver disease cohort patients.
Detailed Description
The effect of gut microbiota on liver disease is also well known and many studies are ongoing. A recently published study summarized the differences in the composition of gut microbiota in non-alcoholic fatty liver, steatohepatitis, and cirrhosis, and reported that metabolites from the changed gut microbiota may be a factor influencing non-alcoholic fatty liver disease (NAFLD) progression. These changes in gut microbiota composition have been reported to affect clinical outcomes in patients by causing an increase in endotoxin, a change in bile acid metabolism, and a decrease in short chain fatty acid. In particular, the reduction of short chain fatty acid is known to be associated with the occurrence of sarcopenia. Sarcopenia, which is common in patients with cirrhosis, which is a representative chronic liver disease, is well known as a poor prognostic factor for patients. Therefore, this study aims to analyze the distribution of gut microbiota observed in patients with sarcopenia through the gut microbiota investigated in the chronic liver disease cohort patient group and the characteristics of the distribution of gut microbiota for each disease corresponding to chronic liver disease.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 24 Years to 82 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who have chronic liver disease (chronic liver disease cohort): alcohol liver disease, non-alcoholic liver disease, liver cirrhosis
- •Patients who consented to a study confirming the gut microbiota
- •Patients with abdominal computed tomography scan taken one month before or after submitting stool for gut microbiota analysis
Exclusion Criteria
- •Patients whose height and weight records are missing from the chart review
Outcomes
Primary Outcomes
Fecal gut microbiota between sarcopenia group and non-sarcopenia group
Time Frame: 2 years
Compare the species and proportions of the gut microbiota between sarcopenia group and non-sarcopenia group
Secondary Outcomes
No secondary outcomes reported